Corporate, Emerging Companies + Venture Capital, and Life Sciences
South San Francisco, CA
Stephen B. Thau
Morrison & Foerster is an invited presenter at BayBio 2009, a one-day conference focusing on Northern California's strength in life sciences product development and commercialization.With public capital markets frozen and venture capital becoming scarce, life sciences companies are increasingly turning to alternative sources of capital to finance their endeavors. Project-based financing can monetize a revenue stream to fund other programs, while government grants and private foundations can support innovative work with non-dilutive capital, and can also provide scientific validation and peer review. Of course, there are pitfalls to avoid with each of these as well. What are the pros and cons of alternative financing options for life sciences companies? This discussion delves into these issues and examines the "how-tos" of implementing strategies for accessing capital in a down-turned market.Moderator:
Stephen B. ThauPartner, Morrison & Foerster LLP
Michael J. EichbergAssociate Director, Business Development, Achaogen, Inc.
Guy Miller, MD, PhDChairman, Chief Executive Officer, Edison Pharmaceuticals
Patricia OlsonDirector of Scientific Activities, California Institute for Regenerative Medicine
Michael S. OstrachChief Business Officer and General Counsel, Dynavax Technologies Corporation
©1996-2018 Morrison & Foerster LLP. All rights reserved.